View source for Definition:Clinical trial insurance

💊 '''Clinical trial insurance''' is a specialized form of [[Definition:Liability insurance | liability coverage]] designed to protect sponsors, investigators, and research institutions against [[Definition:Claim | claims]] arising from injury or adverse events experienced by participants in clinical studies. Pharmaceutical companies, biotech firms, medical device manufacturers, and academic research centers typically procure this coverage as a prerequisite for regulatory approval to conduct human trials — and many jurisdictions mandate it as a condition of ethical review board clearance.

📋 The policy generally covers bodily injury claims brought by trial participants who suffer unexpected side effects, allergic reactions, or other harm directly attributable to the investigational product or study procedures. Coverage extends to legal defense costs, settlements, and court-awarded damages. [[Definition:Underwriting | Underwriters]] assess risk based on the trial's phase (Phase I trials carry higher uncertainty than Phase III), the therapeutic area, the participant population, geographic scope, and the sponsor's track record. Exclusions commonly apply to injuries resulting from protocol violations, known and disclosed risks that participants consented to, or pre-existing conditions unrelated to the trial. Because the exposures are inherently uncertain — the product under study has not yet been fully characterized — [[Definition:Premium | premiums]] can be substantial, and [[Definition:Insurance carrier | carriers]] active in this niche require deep scientific expertise alongside traditional [[Definition:Risk assessment | risk assessment]] capabilities.

🔬 This coverage fills a critical gap in the research ecosystem. Without it, clinical trials could be delayed or abandoned because sponsors lack the financial backstop to indemnify participants, and ethics committees would withhold approval. For insurers, clinical trial insurance represents a technically demanding but profitable specialty line, often written by [[Definition:Lloyd's syndicate | Lloyd's syndicates]] and specialist [[Definition:Surplus lines insurance | surplus lines]] carriers with dedicated life sciences teams. As the global pipeline of biologics, gene therapies, and AI-driven drug candidates expands, demand for this coverage continues to grow — presenting [[Definition:Managing general agent (MGA) | MGAs]] and [[Definition:Insurtech | insurtechs]] with opportunities to streamline placement through digital platforms and more granular [[Definition:Data analytics | data analytics]].

'''Related concepts:'''
{{Div col|colwidth=20em}}
* [[Definition:Liability insurance]]
* [[Definition:Product liability insurance]]
* [[Definition:Life sciences insurance]]
* [[Definition:Professional liability insurance]]
* [[Definition:Lloyd's syndicate]]
* [[Definition:Surplus lines insurance]]
{{Div col end}}